These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35003900)

  • 1. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
    Kono M; Komatsuda H; Yamaki H; Kumai T; Hayashi R; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Kobayashi H; Harabuchi Y
    Oncoimmunology; 2022; 11(1):2021619. PubMed ID: 35003900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [FGFR-targeted therapy in head and neck carcinomas].
    Dietrich D
    HNO; 2021 Mar; 69(3):172-184. PubMed ID: 32519203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.
    Yamaki H; Kono M; Wakisaka R; Komatsuda H; Kumai T; Hayashi R; Sato R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Hayashi T; Kobayashi H; Katada A
    Cancer Immunol Immunother; 2023 Aug; 72(8):2799-2812. PubMed ID: 37173455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
    Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma.
    Ludwig ML; Michmerhuizen NL; Wang J; Birkeland AC; Majchrowski BK; Nimmagadda S; Zhai J; Bhangale A; Kulkarni A; Jiang H; Swiecicki PL; Brenner JC
    Arch Oral Biol; 2023 Dec; 156():105822. PubMed ID: 37844343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
    Kono M; Kumai T; Hayashi R; Yamaki H; Komatsuda H; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Celis E; Kobayashi H; Harabuchi Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3421-3434. PubMed ID: 33866408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.
    Wang HC; Yeh TJ; Chan LP; Hsu CM; Cho SF
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
    Malchers F; Nogova L; van Attekum MH; Maas L; Brägelmann J; Bartenhagen C; Girard L; Bosco G; Dahmen I; Michels S; Weeden CE; Scheel AH; Meder L; Golfmann K; Schuldt P; Siemanowski J; Rehker J; Merkelbach-Bruse S; Menon R; Gautschi O; Heuckmann JM; Brambilla E; Asselin-Labat ML; Persigehl T; Minna JD; Walczak H; Ullrich RT; Fischer M; Reinhardt HC; Wolf J; Büttner R; Peifer M; George J; Thomas RK
    J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37606995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.
    Saddawi-Konefka R; O'Farrell A; Faraji F; Clubb L; Allevato MM; Jensen SM; Yung BS; Wang Z; Wu VH; Anang NA; Msari RA; Schokrpur S; Pietryga IF; Molinolo AA; Mesirov JP; Simon AB; Fox BA; Bui JD; Sharabi A; Cohen EEW; Califano JA; Gutkind JS
    Nat Commun; 2022 Jul; 13(1):4298. PubMed ID: 35879302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma.
    Knitz MW; Darragh LB; Bickett TE; Bhatia S; Bukkapatnam S; Gadwa J; Piper M; Corbo S; Nguyen D; Van Court B; Oweida A; Karam SD
    Cancer Immunol Immunother; 2022 May; 71(5):1049-1061. PubMed ID: 34559306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway.
    Luo X; Qiu Y; Fitzsimonds ZR; Wang Q; Chen Q; Lei YL
    Oncogene; 2024 Feb; 43(6):388-394. PubMed ID: 38177410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Frontier: Head and Neck Cancer Immunoprevention.
    Gutkind JS; Bui JD
    Cancer Prev Res (Phila); 2017 Dec; 10(12):681-683. PubMed ID: 29138137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model.
    Yun J; Saddawi-Konefka R; Goldenson B; Al-Msari R; Bernareggi D; Thangaraj JL; Tang S; Patel SH; Luna SM; Gutkind JS; Kaufman D
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 1 amplification in laryngeal squamous cell carcinoma.
    Monico J; Miller B; Rezeanu L; May W; Sullivan DC
    PLoS One; 2018; 13(1):e0186185. PubMed ID: 29351293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial.
    Hecht M; Frey B; Gaipl US; Tianyu X; Eckstein M; Donaubauer AJ; Klautke G; Illmer T; Fleischmann M; Laban S; Hautmann MG; Tamaskovics B; Brunner TB; Becker I; Zhou JG; Hartmann A; Fietkau R; Iro H; Döllinger M; Gostian AO; Kist AM
    Neoplasia; 2024 Mar; 49():100953. PubMed ID: 38232493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.
    Chen F; Tang C; Yang F; Ekpenyong A; Qin R; Xie J; Momen-Heravi F; Saba NF; Teng Y
    Sci Adv; 2024 Feb; 10(8):eadk3663. PubMed ID: 38394204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer.
    Lin H; Hassan Safdar M; Washburn S; S Akhand S; Dickerhoff J; Ayers M; Monteiro M; Solorio L; Yang D; Wendt MK
    Commun Biol; 2024 Aug; 7(1):963. PubMed ID: 39122837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.
    Popiel D; Stańczak A; Skupińska M; Mikołajczyk A; Stańczak P; Mituła F; Hucz-Kalitowska J; Jastrzębska K; Smuga D; Dominowski J; Delis M; Mulewski K; Pietruś W; Zdżalik-Bielecka D; Dzwonek K; Lamparska-Przybysz M; Yamani A; Olejkowska P; Piórkowska N; Dubiel K; Wieczorek M; Pieczykolan J
    Front Oncol; 2023; 13():1293728. PubMed ID: 38282676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sema6D forward signaling impairs T cell activation and proliferation in head and neck cancer.
    Hirai T; Naito Y; Koyama S; Nakanishi Y; Masuhiro K; Izumi M; Kuge T; Naito M; Mizuno Y; Yamaguchi Y; Kang S; Yaga M; Futami Y; Nojima S; Nishide M; Morita T; Kato Y; Tsuda T; Takemoto N; Kinugasa-Katayama Y; Aoshi T; Villa JK; Yamashita K; Enokida T; Hoshi Y; Matsuura K; Tahara M; Takamatsu H; Takeda Y; Inohara H; Kumanogoh A
    JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.